Gilead Sciences Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (428)

Latest Posts

About This Stock More About This Stock
Week In Review: Alphamab Closes $100 Million Series A For Oncology Candidates
Article By: ChinaBio® Today
Saturday, November 24, 2018 4:09 PM EST
Alphamab Oncology, a clinical-stage Suzhou biopharma, completed a Series A funding with over $100 million in capital. Earlier this year, Alphamab Oncology was spun out of Suzhou Alphamab with seven oncology assets and related technology platforms.
In this article: LLY, CASI, BIIB, GILD
Read
Gilead Selloff On UnitedHeath HIV Promotion Seen As Unwarranted
Article By: The Fly
Wednesday, October 31, 2018 5:11 PM EST
In afternoon trading, shares of Gilead have dropped about 5% to $68.65.
In this article: GILD, UNH
Read
Gilead Sciences (GILD) Q3 Earnings And Revenues Top Estimates
Article By: Zacks Investment Research
Thursday, October 25, 2018 10:12 PM EST
Gilead Sciences came out with quarterly earnings of $1.84 per share, beating the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $2.27 per share a year ago.
In this article: GILD
Read
Week In Review: Shanghai Henlius To File For Hong Kong IPO At Valuation Of Over $1 Billion
Article By: ChinaBio® Today
Saturday, October 6, 2018 5:57 PM EST
Shanghai Fosun Pharma announced it will seek a Hong Kong IPO for Shanghai Henlius Biotech, its monoclonal antibody JV subsidiary The company was established to develop mAb biosimilar drugs, bio-betters and novel mAbs.
In this article: GILD, CBMG
Read
Most Undervalued Stocks Of The S&P 500 – August 2018
Article By: Benjamin Clark
Monday, August 13, 2018 9:00 PM EST
Defensive Investors are defined as investors who need to select only the companies that present the least amount of risk. Here are a few companies for the Defensive investors.
In this article: ADS, DUK, LNC, MHK, MS, PRU, TSN, GILD, CFG, SYF
Read

PARTNER HEADLINES

Latest Tweets for $GILD

No tweets yet!

$GILD

Gilead Crohn's Treatment Is Not The Solution To GLD Revenue Issues
Kurt Benson 3/24/2017 10:12:59 PM

I have to agree with your assessment on $GILD. Do you know anything about $VBIO? I read a promising article here about their having a major breakthrough in #Crohn's research.

www.talkmarkets.com/.../interview-with-vitality-biopharma-inc

Not a lot of info on the company though.

Gilead Crohn's Treatment Is Not The Solution To GLD Revenue Issues
Kirk Sheffield 3/24/2017 10:11:55 PM

I think $GILD will rebound. This isn't the only product they have in their pipeline.

Gilead Crohn's Treatment Is Not The Solution To GLD Revenue Issues
Alpha Stockman 3/24/2017 10:07:45 PM

I've been rather disappointed with #Gilead myself. After reading your article, I'm planning to offload some $GILD.

Gilead Sciences Receives Canadian Approval For HIV Drug
David Reynolds 2/20/2017 10:04:11 PM

The opening up of this market for #GileadSciences should bode well for the stock $GILD.

Gilead Sciences: Cheap Growth Or Value Trap?
Karen Klein 9/13/2016 5:39:48 PM

Excellent analysis, you have effectively convinced me to change my position on #Gilead. $GILD

3 Cult Stocks To Avoid In 2015
Bruce Powers 1/26/2015 8:01:06 AM

Great article and glad to read the reasoning to consider $GILD as a safer investment short, mid and long term.

3 Cult Stocks To Avoid In 2015
BreakingBad News 1/25/2015 6:09:51 PM

Sorry all, thanks for the clarification. My bad! Now that I've read it through, it all makes total sense. $GILD, $BAC, $WFM, and $VA are my plays for 2015.

3 Cult Stocks To Avoid In 2015
BreakingBad News 1/25/2015 4:48:08 PM

I'd say this is a minority view, I've seen several others stating that $GILD was a stock to buy this year.

1 to 8 of 8 comments